Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Novel systemic therapy against malignant pleural mesothelioma

“…The concept of a "magic bullet" delivering a potent chemotherapeutic to cancer cells and not normal healthy cells was first proposed over a century ago (142). Today, standard of care oncology practice utilizes antibody-drug conjugates with the approval of trastuzumab-emtansine (TDM1) (143) and brentuxumab vedotin (144)(145)(146). Antibody drug conjugates seek to utilize the specificity of antibody affinity to deliver highly potent cytotoxic agents specifically to cancer cells.…”

Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation

“…After high-dose therapy, the antibody-drug conjugate brentuximab vedotin (BV) demonstrated very promising results both as consolidation and salvage treatment and is approved in this setting. 7,8 In highly refractory cases alloSCT is considered as a therapeutic option in eligible patients. 9 Recently, checkpoint inhibition by nivolumab demonstrated a remarkable overall response rate of 87% including 17% complete remissions (CR) in 23 patients with r/r HL.…”

Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them

“…For example, the antibody drug conjugate BV is FDA approved in R/R CHL following ASCT and as consolidation therapy in high-risk patients post ASCT [14,15]. The active agent in BV is monomethyl auristatin E (MMAE), a microtubule disrupting agent that ultimately causes apoptotic cell death.…”